Updated:
Abivax
Abivax is a single-asset biotech advancing obefazimod through Phase 3 trials for ulcerative colitis, led by Marc de Garidel.
Abivax
Abivax was founded in 2013 as a spinout from the Institut de Génétique Moléculaire de Montpellier, with an early pipeline built on antiviral research that later pivoted to chronic inflammatory diseases. Marc de Garidel, former CEO of Ipsen, took the top role in 2022 and refocused the company almost entirely on obefazimod, an oral small molecule that upregulates a microRNA to reduce inflammation in the gut. The company's scientific foundation rests on these molecular mechanisms originally explored for HIV, but the commercial thesis hinges on a single disease with annual treatment costs exceeding $30,000 per patient in the United States. Abivax's strategy concentrates execution risk behind one Phase 3 asset — running parallel pivotal trials in ulcerative colitis and a Phase 2b trial in Crohn's disease — with no preclinical or discovery-stage programs in active development. The lead trial enrolled over 1,200 patients globally across 36 countries including the United States, Germany, Japan, and Canada, with top-line data expected in the first quarter of 2025. The company raised €130 million in a 2023 private placement with TCG Capital and Venrock, and listed American Depositary Shares on Nasdaq in October 2023 to access US healthcare investors. A February 2024 financing brought in an additional €49 million through a reserved capital increase. Abivax operated with 55 employees as of mid-2024, headquartered in Paris with clinical operations in the United States, and market capitalization hovering near €600 million after a correction from its 2023 highs. The company maintains a research agreement with the CNRS and the University of Montpellier for its foundational biology platform. Marc de Garidel holds the dual CEO and board chair title, and the company announced in September 2024 the appointment of a new chief medical officer to oversee late-stage clinical data readouts. Abivax has no disclosed family-office backing or adjacent philanthropic vehicle. Abivax is structurally distinct from diversified biotech peers in its absolute single-asset concentration — no fallback program, no licensing revenue, and no preclinical pipeline to buffer a failure in Phase 3. The company's entire valuation rests on the binary outcome of one pivotal readout in 2025, which creates a risk profile more akin to an asset-specific special-purpose vehicle than a traditional drug developer.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Paris
Corporate office
Paris, France
Principals
Marc de Garidel
Chief Executive Officer
Didier Blondel
Chief Financial Officer
Sheldon Sloan
Chief Medical Officer
Sector focus
Frequently asked questions
What is obefazimod, and why does it matter for Abivax's valuation?
Obefazimod is an oral small-molecule drug candidate that upregulates miR-124, a microRNA that dampens inflammatory signaling in the gut. Abivax's entire investment thesis derives from ongoing Phase 3 trials in ulcerative colitis, with top-line data reported in Q1 2025. The company has no backup asset with comparable scale; failure here would likely trigger a restructuring. This single-asset risk profile is the dominant consideration for any allocator evaluating the stock.
How does Abivax fund its clinical operations?
Abivax operates as a publicly traded company on Euronext Paris and Nasdaq, funding operations entirely through equity raises and listed market access. A May 2023 private placement led by TCG Capital and Venrock brought in €130 million, and a Nasdaq listing in October 2023 provided a pathway to US biotech investors. The company raised an additional €49 million through a reserved capital increase in February 2024. No pharmaceutical partner is currently providing upfront or milestone payments for the pivotal program.
Who runs investment decisions at Abivax?
Abivax is a publicly traded biotechnology operating company, not an investment fund. All capital allocation — including trial design, geographic expansion, and financing strategy — is overseen by CEO Marc de Garidel and ratified by the board of directors. De Garidel previously ran Ipsen, a €2 billion market-cap specialty pharma company, and brought a commercial-stage mindset to the late-stage pipeline.
Which sectors does Abivax explicitly avoid?
Abivax is exclusively focused on chronic inflammatory diseases, with all current resources directed at ulcerative colitis and Crohn's disease. The antiviral programs that defined its early years — including dengue and Ebola candidates — were shelved as the company pivoted wholly toward the inflammatory bowel disease market opportunity.
What investment stages do Abivax shareholders effectively underwrite?
As a public company, Abivax shareholders underwrite Phase 3 and pre-commercialization execution risk for a single drug candidate. This is distinct from venture-stage biotech or diversified life-science funds: the binary event is a regulatory readout, not a Series A to Series B transition. Allocators treat this as a pre-revenue biotech with late-stage clinical risk and no product on the market.
Is Abivax structured as a family office or does it operate more like a traditional biotech?
Abivax is a standard Euronext- and Nasdaq-listed biotechnology company with no family-office governance characteristics. It is not a single-family office, multi-family office, or investment partnership. Institutional and retail shareholders own the firm through publicly traded equity, and the management team operates under French corporate law with a one-tier board structure.
What is Abivax's known posture on partnership or M&A ahead of the Phase 3 readout?
Abivax has repeatedly stated it intends to retain full global rights to obefazimod through the pivotal data readout, rather than striking a co-development or licensing deal that would dilute the commercial upside. CEO Marc de Garidel told analysts on the Q1 2024 earnings call that partnering discussions would be considered only after the company has data in hand to maximize negotiating leverage. This posture concentrates both upside and downside in the hands of public shareholders.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: